Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines

Cell Death and Differentiation

Volumn 5, Issue 8, 1998, Pages 678-686

  Danks, Mary K ^a   Whipple, David O ^a   McPake, Christina R ^a   Lu, Daiying ^a   Harris, Linda C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

1801; 421; BP53.12; DO1; DO7; Immunoblotting; Immunofluorescence; p53

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; CELL FRACTIONATION; CYTOPLASM; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

EID: 0031816840     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400408     Document Type: Article

References (45)

1. Ayan I, Dogan O, Kebudi R, Bavbek B, Alatli C, Dervisoglu S, Disci R and Demiryont M (1997) Immunohistochemical detection of p53 protein in rhabdomyosarcoma: Association with clinicopathological features and outcome. J. Ped. Hematol/ Oncol 19 48-53
2. Bairoch A and Apweiler R (1997) The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res. 25: 31-36
3. Banks L, Matlashiewski G and Crawform L (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159: 529-534
4. Bhattacharjee MB and Bruner JM (1997) p53 Protein in pediatric malignant astrocytomas: A Study of 21 patients. J Neuro-Oncol. 32: 225-233
5. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF and Linnoila RI (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogens 7: 743-749
6. Bonsing BA, Corver WE, Gorsira MCB, vanVliet M, Oud PS, Cornelisse CJ and Fleuren GJ (1997) Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry Cytometry 28. 11-24
7. Brown CR, Doxsey SJ, White E and Welch WJ (1994) Both viral (adenovirus E1B) and cellular (hsp70, p53) components interact with centrosomes. J. Cell. Phys 160: 47-60
8. Cattoretti G, Rilke F, Andreola S, D'Amato L and Delia D (1988) Expression in breast cancer. Int. J Cancer 41: 178-183
9. Danks MK, Garrett KE, Marion RC and Whipple DO (1996) Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res. 56. 1664-1673
10. Danks MK, Pawlik CA, Whipple DO and Wolverton JS (1997) Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin. Cancer Res. 3: 1731-1738
11. David-Pfeuty T, Chakrani F, Dry K and Nouvian-Dooghe Y (1996) Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth and Differentiation 7: 1211-1225
12. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K and Smith HS (1994) Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54. 499-505
13. Domagala W, Harenzga B, Szadowska A, Mariewski M, Weber K and Osbom M (1993) Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am. J Pathol 142: 669-674
14. El-Deiry WS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B (1994) WAF1/CIP1 is induced upon p53-mediated growth arrest and apoptosis. Cancer Res, 54: 1169-1174
15. Esposito V, Balda A, DeLuca A, Claudio PP, Signoriello G, Bolognese A, Centonze P, Giordano GG, Caputi M, Baldi F and Giordano A (1997) p53 Immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res 17: 733-736
16. Fan S, ElDiery WS, Bae I, Freeman J, Jondel D, Blatia K, Fornace AJ, Magrath I, Kohn KW and O'Connor PM (1994) p53 Gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54: 5824-5830
17. Fritsche M, Haessler C and Bradner G (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA damage. Oncogene 8. 307-318
18. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, Larsen AK and Riou JF (1996) Modulation of DNA topoisomerase I activity by p53. Biochemistry 35: 5778-5786
19. Goldsmith ME, Gudas JM, Schneider E and Cowan KH (1995) Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J. Biol Chem. 270. 1894-1898
20. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H and Houghton PJ (1987) Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res. 47: 4501-4507
21. Jenkins JR, Chumakov P, Addison C, Sturzbecher HW and Wade-Evans A (1988) Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 Tantigen. J. Virol. 62: 3902-3906
22. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819
23. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51 6304-6311
24. Kohn KW, Jackman J and O'Connor PM (1994) Cell cycle control and cancer chemotherapy J. Cell. Biochem. 54. 440-452
25. Kraiss S, Quaiser A, Oren M and Montenarh M (1988) Oligomerization of oncoprotein p53. J. Virol. 62. 4737-4744
26. Levine AJ, Momand J and Finlay CA (1991) The p53 tumor suppressor gene. Nature 351: 453-455
27. Lows SW, Ruley HE, Jacks T and Houseman E (1993) p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74. 957-967
28. Milner J and Watson JV (1990) Addition of fresh medium induces cell cycle and conformational changes in p53, a tumor suppressor protein Oncogene 5: 11683-11690
29. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD and Gazdar A (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180
30. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier F and Zambetti GP (1996) Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16: 1126-1137
31. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
32. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A and Oren M (1986) Specific interaction between the p53 cellular tumor antigen and major heat shock proteins. Nature (London) 320: 182-185
33. Saylors RL, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B and Brodeur GM (1991) Infrequent p53 gene mutations in medulloblastomas Cancer Res. 51: 4721-4723
34. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ and Shenk T (1992) Wild-type p53 binds to the TATA-binding protein and represses transcription Proc. Natl. Acad. Sci. USA 89: 12028-12032
35. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ and Rotter V (1991) Nuclear localization is essential for the activity of p53 protein Oncogene 6. 2055-2065
36. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J (1996) The p53 gene in breast cancer Prognistic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Ints 88: 173-182
37. Spandau DF (1994) Distinct conformations of p53 are observed at different stages of keratinocyte differentiation Oncogene 9. 1861-1868
38. cdc2 in mammalian cells: implications for cell cycle control and oncogenesis Oncogene 5: 795-801
39. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD (1989) p53 a frequent target for genetic abnormalities in lung cancer Science 246, 491-494
40. Thomas MD, McIntosh GG, Anderson JJ, MdKena DM, Parr AH, Johnstone R. Lennard TWJ, Horne CHW and Angus B (1997) A Novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status J. Clin. Pathol. 50: 143-147
41. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C and Walker RA (1991) Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6: 513-521
42. Wemess BA. Levine AJ and Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248. 76-79
43. Yoo J, Lee HK, Kang CS, Park WS, Lee JY and Shim SI (1997) p53 Gene mutations and p53 protein expression in human soft tissue sarcomas. Arch. Pathol. Lab. Med 121: 395-399
44. Zambetti GP and Levine AJ (1993) A Comparison of the b iological activities of wild-type and mutant p53. FASEB J. 7. 855-865
45. Zheng CF and Guan KL (1994) Cytoplasmic localization of the mitogen-activated protein kinase activator MEK. J. Biol Chem. 269: 19947-19952